

Key Investor Information

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.


L&G Pharma Breakthrough UCITS ETF

Share Class USD Accumulating ETF - ISIN: IE00BF0H7608. The Fund is a sub-fund of Legal & General UCITS ETF Plc (the "Company").
Managed by LGIM Managers (Europe) Limited, a member of the Legal & General group (the "Manager")

OBJECTIVES AND INVESTMENT POLICY

- The L&G Pharma Breakthrough UCITS ETF (the "Fund") is a passively managed exchange traded fund ("ETF") that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the "Index"), subject to the deduction of the ongoing charges and other costs associated with operating the Fund.
- The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.
- Dealing.** Shares in this Share Class (the "Shares") are denominated in USD and can be bought and sold on stock exchanges by ordinary investors using an intermediary (e.g. a stockbroker). In normal circumstances, only Authorised Participants may buy and sell Shares directly with the Company. Authorised Participants may redeem their Shares on demand in accordance with the "Dealing Timetable" published on <http://www.lgim.com>.
- Index.** The Index is comprised of bio-technology companies which are publically traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An "orphan drug" is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. A company is only eligible for inclusion in the Index if (1) it is of a sufficient size (determined by reference to the total market value of the proportion of its shares that are publically traded) and (2) it is sufficiently "liquid" (a measure of how actively its shares are traded on a daily basis). The universe of companies out of which the Index selection is made is refreshed annually in April. However, the Index is reconstituted semi-annually in April and October in accordance with the full selection criteria and all companies are equally weighted within the Index. On a monthly basis, the weight of each company is assessed and, if any of them exceeds 15% of the Index, the weights of all companies are adjusted so that they are again equally weighted within the Index.
- Replication.** The Fund will primarily invest directly in the securities represented in the Index in similar proportions to their weightings in the Index. The fund may also invest in (1) bio-technology companies that are not constituents of the Index that have similar risk and performance characteristics to the companies contained in the Index and (2) financial derivative instruments ("FDIs") (i.e. investments the prices of which are based on the companies contained in the Index and/or such other bio-technology companies). Adjustments to the Fund's portfolio, including as a result of a reconstitution of the Index, will incur transaction costs.
- Dividend Policy.** This Share Class does not intend to pay dividends. Any income which may result from the Fund's investments will be re-invested into the Fund.

RISK AND REWARD PROFILE



- The Fund is rated 6 due to the nature of its investments and its risks. The rating is calculated based on historical data and may not be a reliable indication of the Fund's future risk profile. The risk category may shift over time. The lowest category on the above scale does not mean "risk free".
- As the Index includes micro, small and medium-sized publicly traded companies, the Fund is subject to the risk that such companies may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies or the stock market as a whole.
- Companies that are actively engaged in the research, development and manufacture of orphan drugs are particularly vulnerable to the risk that, following lengthy and costly development periods, a drug may not ultimately enter into revenue-generating commercial production as a result of: (i) clinical trial failures, (ii) governmental intervention or refusal to grant appropriate approvals and/or licenses for clinical trials or commercial production and/or (iii) a lack of commercial viability. Additionally, the emergence of cheaper or more effective drugs could lead to a decline in the revenues of such companies. Such factors could lead to a decline in the value of the companies represented in the Index and therefore the Fund.
- Third party service providers (such as counterparties entering into FDIs with the Fund or the Company's depository) may go bankrupt and fail to pay money due to the Fund or return property belonging to the Fund.
- If the Index provider stops calculating the Index or if the Fund's license to track the Index is terminated, the Fund may have to be closed. It may not always be possible to buy and sell Shares on a stock exchange or at prices closely reflecting the NAV. There is no capital guarantee or protection on the value of the Fund. Investors can lose all the capital invested in the Fund.
- Please refer to the "Risk Factors" section of the Company's Prospectus and the Fund Supplement.



CHARGES FOR THE FUND


The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential return from your investment.

One-off charges taken before or after you invest	
Entry charge	0.00%*
Exit charge	0.00%*
This is the maximum that might be taken out of your money before it is invested or before the proceeds of your investment are paid out.	
Charges taken from the Share Class over a year	
Ongoing charge	0.49%
Charges taken from the Share Class over a year	
Performance fee	None

*Authorised Participants dealing directly with the Company will pay related transaction costs

- Ordinary investors (i.e. who buy and sell Shares on stock exchanges) are not charged entry or exit charges by the Company but may be charged dealing costs and fees by their stockbroker. Please consult your stockbroker and/or investment adviser for details of such fees.
- The ongoing charges figure is based on expenses for the 12 month period ended 31 December 2021 and may vary from year to year. The ongoing charges figure excludes portfolio transaction costs (except for the custody transaction costs paid to the Depositary which are included).
- For more information about charges, please see the “Fees and Expenses” section of the Company’s Prospectus and the “Dealing Procedures” and “Dealing Information” sections of the Fund Supplement which are available at: <http://www.lgim.com>.

PAST PERFORMANCE



- The Fund has been in existence since 15 December 2017. This Share Class has been in existence since 15 December 2017.
- The chart shows the annual performance of the Share Class in USD for each full calendar year over the period displayed in the chart.
- Ongoing charges have been included in the calculation of past performance. Any entry/exit charges have been excluded from the calculation.
- Past performance is not a guide to future performance.

PRACTICAL INFORMATION

- The Fund’s depositary is The Bank of New York Mellon SA/NV, Dublin Branch.
- The Fund is one of a number of sub-funds of the Company. The assets and liabilities of each sub-fund are segregated from each other by Irish law. Although the rights of investors and creditors are normally limited to the assets of each sub-fund, the Company is a single legal entity that may operate in jurisdictions which may not recognise such segregation.
- The Company is resident in Ireland for taxation purposes. This may have an impact on your personal tax position. Please consult your investment or tax adviser for advice on your own tax liabilities.
- The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Company’s Prospectus.
- Further information about the Fund and the Share Class can be obtained from the Company’s Prospectus and Fund Supplement and the annual and interim financial statements (that are prepared for the Company as a whole), which are available, in addition to the latest available NAV for the Share Class and details of the Fund’s portfolio, at: <http://www.lgim.com>. These documents are available free of charge in English and certain other languages.
- Switching of shares between this Share Class and other share classes of the Fund and/or other sub-funds of the Company is not permitted.
- An indicative intra-day net asset value (“iNAV”) for the Share Class will be available at: <https://www.solactive.com/>.
- Details of the Manager’s up-to-date policy in respect of remuneration, including a description of how remuneration and benefits are calculated and the identities of the persons responsible for awarding same can be accessed from the following website: <http://www.lgim.com>. A paper copy is also available free of charge from the Manager upon request.